Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology · Myeloid/Lymphoid Neoplasm With JAK2 Rearrangement

Survivorship and Long-Term Monitoring

At a Glance

Long-term care for JAK2-rearranged myeloid/lymphoid neoplasm is individualized and may combine blood counts, molecular testing, repeat bone marrow exams, symptom-based scans, and heart checks after hypereosinophilia. Emotional support can also help with scanxiety.

Managing a myeloid/lymphoid neoplasm (MLN) with a JAK2 rearrangement is a long-term commitment. Because this disease is a “chameleon” that can change its behavior over time, your medical team will use an individualized combination of blood tests, bone marrow exams, and advanced genetic monitoring [1][2].

The Importance of Ongoing Monitoring

Standard blood work, like a Complete Blood Count (CBC), is essential but only tells part of the story. Your doctors are also looking for “molecular” signs of the disease.

  • Molecular Response Tracking: If a validated quantitative assay exists for your specific fusion, doctors may measure the exact amount of the JAK2 transcript in your blood or marrow [3][4]. While a rising fusion level can precede clinical changes, these results must be interpreted alongside your marrow findings and symptoms [5].
  • Repeat Bone Marrow Biopsies: These are the gold standard for checking if the disease is evolving. They allow doctors to check for blasts, fibrosis (marrow scarring), and new genetic mutations [5][6].
  • Extramedullary Surveillance: Because this cancer can sometimes hide outside the marrow, your doctor may order scans based on your symptoms [1][2].

Understanding Your Prognosis

Your long-term outlook depends heavily on how the disease first appeared. Because it is so rare, precise individual predictions are difficult, and outcomes are highly individualized [7].

Generally, patients presenting in a chronic phase (like MPN or MDS) may have a slower progression and a more predictable response to initial treatment compared to those presenting in an acute blast phase (like AML or ALL), which requires aggressive leukemia-style therapy [7][8].

Long-Term Heart and Lung Health

If you have a history of hypereosinophilia, your team will evaluate if you need cardiac monitoring [9]. Past damage from eosinophils can lead to heart stiffness over time [10].

Depending on your history, this may include:

  • Echocardiograms: Used to check heart function and look for clots [11][10].
  • Cardiac MRI: Provides a more detailed look at the heart muscle to identify “silent” scarring [11][12].
  • Biomarkers: Blood tests for troponin or NT-proBNP [13][14].

Coping with “Scanxiety” and Uncertainty

Living with a rare, unpredictable cancer takes a significant psychological toll. It is common to experience scanxiety—intense anxiety before a follow-up scan or biopsy [15][16].

Research shows that patients with rare blood cancers often face higher levels of distress [17][18]. To manage this:

  • Acknowledge the Uncertainty: Rare diseases often have fewer “standard” answers.
  • Seek Specialized Support: Ask for a referral to a psycho-oncologist or a social worker who understands hematologic cancers [19][20].
  • Stay Informed but Boundaried: Focus on your specific molecular trends and the plan built by your expert team [21][22].

Common questions in this guide

How is a JAK2-rearranged myeloid/lymphoid neoplasm monitored over time?
Follow-up may combine complete blood counts, molecular testing when a validated assay is available, repeat bone marrow examinations, and scans guided by symptoms. The schedule is individualized based on your disease phase, test results, symptoms, and treatment history.
What could a rising JAK2 fusion level mean?
A rising fusion level may appear before other clinical changes, but it does not determine progression by itself. Doctors interpret the result together with blood counts, bone marrow findings, symptoms, and other molecular results.
When might I need another bone marrow biopsy?
A repeat biopsy may be used to look for changes in blast levels, marrow scarring, or new genetic mutations. Your hematology team may recommend one when blood counts, symptoms, molecular results, or other findings suggest that the disease may be changing.
Does a history of hypereosinophilia affect heart monitoring?
It may. Depending on your history and current eosinophil levels, your team may use an echocardiogram, cardiac MRI, or blood tests such as troponin and NT-proBNP to check for heart stiffness, clots, or silent scarring.
How can I manage scanxiety during long-term follow-up?
Anxiety before scans or biopsies is common, especially with a rare and unpredictable blood cancer. A psycho-oncologist, counselor, or social worker can help you cope while your care team helps you focus on your own test trends and monitoring plan.
Does the phase in which the disease first appears affect my outlook?
It can. A chronic-phase presentation, such as an MPN or MDS pattern, may progress more slowly than an acute blast-phase presentation such as AML or ALL, but individual outcomes vary and are difficult to predict because this disease is rare.

Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

    Metzgeroth G, Steiner L, Naumann N, et al.

    Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

    PMID: 37454239
  2. 2

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  3. 3

    Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.

    Schwaab J, Naumann N, Luebke J, et al.

    American journal of hematology 2020; (95(7)):824-833 doi:10.1002/ajh.25825.

    PMID: 32279331
  4. 4

    Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.

    Chen JA, Hou Y, Roskin KM, et al.

    Blood advances 2021; (5(17)):3492-3496 doi:10.1182/bloodadvances.2020004174.

    PMID: 34505882
  5. 5

    TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.

    Lazarevic V, Lilljebjörn H, Olsson-Arvidsson L, et al.

    Genes, chromosomes & cancer 2024; (63(8)):e23261 doi:10.1002/gcc.23261.

    PMID: 39105620
  6. 6

    The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia.

    Lee WY, Pfau RB, Choi SM, et al.

    Cold Spring Harbor molecular case studies 2020; (6(2)) doi:10.1101/mcs.a004937.

    PMID: 32238402
  7. 7

    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

    Kaplan HG, Jin R, Bifulco CB, et al.

    The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.

    PMID: 35472244
  8. 8

    Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.

    Zhang L, Shah B, Zhang Y, et al.

    Human pathology 2023; (136()):1-15 doi:10.1016/j.humpath.2023.03.002.

    PMID: 36958463
  9. 9

    Evaluation of myocardial performance by serial speckle tracking echocardiography in diagnosis and follow-up of a patient with eosinophilic myocarditis.

    Sharifkazemi M, Rezaian G, Lotfi M

    Echo research and practice 2023; (10(1)):1 doi:10.1186/s44156-022-00013-6.

    PMID: 36698163
  10. 10

    Normalization of left ventricular filling pressure after cardiac surgery for the Loeffler's endocarditis: a case report.

    Carcaterra A, Mock S, Müller H, Testuz A

    European heart journal. Case reports 2021; (5(6)):ytab189 doi:10.1093/ehjcr/ytab189.

    PMID: 34263118
  11. 11

    Loeffler's Endocarditis: An Integrated Multimodality Approach.

    Polito MV, Hagendorff A, Citro R, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2020; (33(12)):1427-1441 doi:10.1016/j.echo.2020.09.002.

    PMID: 33129649
  12. 12

    Contribution of imaging modalities to eosinophilic myocarditis diagnosis: a case report.

    Farhat N, Bouhabib M, Joye R, et al.

    European heart journal. Case reports 2022; (6(2)):ytac058 doi:10.1093/ehjcr/ytac058.

    PMID: 35295721
  13. 13

    Hypereosinophilic syndrome: considerations for the cardiologist.

    Bondue A, Carpentier C, Roufosse F

    Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

    PMID: 34172539
  14. 14

    Heart failure and predictors of outcome in eosinophilic myocarditis: a real-world cohort study.

    Ullrich FTH, Schönermarck U, Milger K, et al.

    Frontiers in medicine 2026; (13()):1887831 doi:10.3389/fmed.2026.1887831.

    PMID: 42718441
  15. 15

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571
  16. 16

    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

    Bauml JM, Troxel A, Epperson CN, et al.

    Lung cancer (Amsterdam, Netherlands) 2016; (100()):110-113 doi:10.1016/j.lungcan.2016.08.002.

    PMID: 27597289
  17. 17

    Psychological distress and quality of life in patients with indolent non-Hodgkin lymphoma.

    Kuiper JW, Custers JAE, Kleinjan A, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026; (34(5)).

    PMID: 42082740
  18. 18

    A chain mediation model reveals the association between metacognition and quality of life in hematologic tumor patients.

    Cheng C, Zheng M, Yan F, et al.

    Scientific reports 2024; (14(1)):18446 doi:10.1038/s41598-024-69027-w.

    PMID: 39117715
  19. 19

    JPOS/JASCC clinical guidelines for psychological distress in adult cancer patients: a summary of recommendations.

    Fujisawa D, Yoshikawa E, Fujimori M, et al.

    Japanese journal of clinical oncology 2026; (56(3)):324-336 doi:10.1093/jjco/hyaf209.

    PMID: 41459813
  20. 20

    Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial.

    El-Jawahri A, Luskin MR, Greer JA, et al.

    Cancer 2023; (129(7)):1075-1084 doi:10.1002/cncr.34645.

    PMID: 36655338
  21. 21

    Exploring psychological distress, appraisal, and coping during the scan result journey: a qualitative study of young and middle-aged Chinese adults with advanced cancer.

    Li X, Lu Y, Fan Y, et al.

    BMC cancer 2026; (26(1)).

    PMID: 41906115
  22. 22

    Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.

    Zhang Y, Nguyen L, Lu CM, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(3)):e150-e163 doi:10.1016/j.clml.2022.12.008.

    PMID: 36624015

This page explains survivorship and monitoring for a JAK2-rearranged myeloid/lymphoid neoplasm for educational purposes and does not replace medical advice. Your hematology team should tailor testing, cardiac follow-up, and emotional support to your history.